comparemela.com

Amyloid Diseases News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer s at the AD/PD™ 2024 Annual Meeting -February 21, 2024 at 08:02 am EST

- Oral presentation to explore drug effect of sabirnetug on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind assay.

United statesErika clineDaniel oconnellJessica laubAlex braunInternational nonproprietary namesExchange commissionAcumen pharmaceuticalsInternational conference on alzheimerDrug administrationDrug developmentAcumen pharmaceuticals incUnited states adopted nameInternational conferenceDanielo connellChief executive officer

vimarsana © 2020. All Rights Reserved.